Stocks › ETON
Eton Pharmaceuticals, Inc.
ETON·Nasdaq·
United States·USD
United States·USD$54.77
-0.85 (-1.53%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ETON
Eton Pharmaceuticals, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ETONS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ETON by members of U.S. Congress · 0 on record
No congressional trades in ETON on record.
Whale Activity
Position changes in ETON reported for 2026-06-30 by 11 tracked institutional filers
- Increased3
- New2
- Held0
- Decreased3
- Closed1
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 1.9M | $68.6M | increased |
| Nantahala Capital Management, LLC | 1.2M | $42.6M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 976.6K | $35.4M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 194.6K | $7.0M | increased |
| D. E. Shaw & Co., Inc. | 188.5K | $6.8M | new |
| CANNELL CAPITAL LLC | 170.7K | $6.2M | — |
| TWO SIGMA INVESTMENTS, LP | 116.3K | $4.2M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 52.3K | $1.9M | decreased |
| CITADEL ADVISORS LLC | 49.0K | $1.8M | decreased |
| Point72 Asset Management, L.P. | 44.9K | $1.6M | new |
| Millennium Management LLC | 0 | $0 | closed |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ETON insiders, by quarter · Form 4
Recent Insider Transactions
126 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Krempa DavidChief Business Officer | Sale | −4,166 | $55.07 | $229K | Oct 6, 2026 | Form 4 ↗ |
| MAIER PAUL VDirector · Director | Sale Amended | −36.4K | $58.64 | $2.1M | Aug 28, 2026 | Form 4 ↗ |
| MAIER PAUL VDirector · Director | Sale Amended | −13.5K | $60.21 | $812K | Aug 28, 2026 | Form 4 ↗ |
| MAIER PAUL VDirector · Director | Sale Amended | −128 | $61.77 | $8K | Aug 28, 2026 | Form 4 ↗ |
| Krempa DavidChief Business Officer | Sale | −25.0K | $65.07 | $1.6M | Aug 24, 2026 | Form 4 ↗ |
| BRYNJELSEN SEANPresident & CEO · Director | Sale | −7,342 | $62.12 | $456K | Aug 20, 2026 | Form 4 ↗ |
| BRYNJELSEN SEANPresident & CEO · Director | Sale | −47.3K | $60.17 | $2.8M | Aug 20, 2026 | Form 4 ↗ |
| BRYNJELSEN SEANPresident & CEO · Director | Sale | −36.4K | $61.11 | $2.2M | Aug 20, 2026 | Form 4 ↗ |
| BRYNJELSEN SEANPresident & CEO · Director | Sale | −8,978 | $62.65 | $562K | Aug 19, 2026 | Form 4 ↗ |
| Opaleye Management Inc. | Sale Amended | −15.0K | $37.54 | $563K | Jul 14, 2026 | Form 4 ↗ |
| Opaleye Management Inc. | Sale Amended | −13.3K | $37.54 | $500K | Jul 14, 2026 | Form 4 ↗ |
| Opaleye Management Inc. | Sale | −6,685 | $38.37 | $257K | Jul 7, 2026 | Form 4 ↗ |
| Opaleye Management Inc. | Sale | −20.0K | $38.37 | $767K | Jul 7, 2026 | Form 4 ↗ |
| Opaleye Management Inc. | Sale | −10.0K | $38.00 | $380K | Jul 6, 2026 | Form 4 ↗ |
| Opaleye Management Inc. | Sale | −65.0K | $37.39 | $2.4M | Jul 2, 2026 | Form 4 ↗ |
| Opaleye Management Inc. | Sale | −25.0K | $37.39 | $935K | Jul 2, 2026 | Form 4 ↗ |
| Adams Jennifer McKieDirector | Sale | −50.0K | $32.48 | $1.6M | Jun 17, 2026 | Form 4 ↗ |
| Adams Jennifer McKieDirector | Option exercise | +50.0K | $3.78 | $189K | Jun 17, 2026 | Form 4 ↗ |
| BRYNJELSEN SEANPresident & CEO · Director | Sale | −148 | $32.67 | $5K | May 28, 2026 | Form 4 ↗ |
| BRYNJELSEN SEANPresident & CEO · Director | Sale | −119.9K | $31.88 | $3.8M | May 28, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ETON · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF iShares Trust | 694.0K | $25.1M | 0.03% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 684.8K | $24.8M | 0.00% | Jun 30, 2026 |
| Oberweis Micro-Cap Fund OBERWEIS FUNDS | 483.9K | $17.5M | 1.08% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 291.9K | $13.5M | 0.04% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund TIAA-CREF Funds | 253.4K | $11.8M | 0.29% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund Fidelity Securities Fund | 253.0K | $11.7M | 0.13% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 271.1K | $9.8M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 246.5K | $8.9M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Growth K6 Fund Fidelity Securities Fund | 132.0K | $6.1M | 0.13% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF SPDR SERIES TRUST | 154.4K | $5.6M | 1.30% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list ETON's shares (CUSIP 29772L108), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 1.9M shares6.9%
Jul 28, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Eton Pharmaceuticals, Inc. as client
No lobbying filings found naming Eton Pharmaceuticals, Inc. as the client.
Government Contracts
Federal awards to Eton Pharmaceuticals, Inc. · USAspending
No federal contract awards found for Eton Pharmaceuticals, Inc..
U.S. Patents
Recent USPTO applications naming Eton Pharmaceuticals, Inc.
No USPTO patent applications found for Eton Pharmaceuticals, Inc..
Annual Financials
From ETON's 10-K filings · XBRL
No annual XBRL figures on record for ETON. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in ETON's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 8.01, 9.01Other eventsSep 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 13, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.01, 9.01Material agreement · Acquisition or dispositionAug 5, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeAug 4, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJul 29, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 9, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.01, 9.01Material agreement · Acquisition or dispositionMay 19, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 14, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsMay 1, 2026
EDGAR ↗
About Eton Pharmaceuticals, Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersDEER PARK, IL
IncorporatedDE
SEC CIK0001710340 ↗